Announced Mon, 29 Jun · 11:08 IST
Board approves pharma unit acquisition plan and Rs 300 Crore fundraise
Board & Shareholder Meetings View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.9%1-day move
₹88.00
prior close
—
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+1.9+0.0-0.1-3.5-4.5-9.8-6.9———
Up moveDown movePending
AI summary
Board met on 29 June 2026 and approved two key decisions. First, authorised the Whole-time Director to evaluate and negotiate acquisition of USFDA, EU-GMP or WHO-GMP compliant pharmaceutical manufacturing units in India to expand capacity. Second, authorised the CFO to raise up to Rs 300 Crore through convertible or non-convertible instruments such as CCDs, CCPS or NCDs via private placement, subject to shareholder approval.
Likely market impact
Potential capacity expansion and large fundraise could dilute existing shareholders; acquisition targets yet to be finalised.